## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.8% in mid entry zone (4.0-10.0%), top 3% cross-sectional ranking. Caution: MRS_5 (-1.0%) diverging from MRS_20, watch for reversal. Outperforming sector by 7.2%. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($55.91)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Swedbank AB Buys 35,000 Shares of BioMarin Pharmaceutical Inc. $BMRN**
- Source: MarketBeat | 20251226T110947 | Neutral | Relevance: 100%
- Swedbank AB increased its stake in BioMarin Pharmaceutical Inc. by 8.1% in the third quarter of 2025, purchasing an additional 35,000 shares to hold a total of 466,943 shares valued at approximately $25.29 million. Other major institutional investors like AQR Capital Management and Viking Global Investors also increased their positions in the biotechnology company. Despite the increased institutional ownership, BioMarin missed its Q3 EPS estimates and received revised price targets from several analysts, though the consensus remains a "Moderate Buy."

**2. Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets**
- Source: RTTNews | 20251226T140947 | Somewhat-Bullish | Relevance: 94%
- In a holiday-shortened week, the biotech sector saw a mix of FDA approvals and rejections, significant acquisition deals, and key clinical trial readouts. Regulatory successes included FDA nods for Roche's Lunsumio VELO and Agios's AQVESME, while Sanofi's Tolbrutinib faced a setback. BioMarin and Sanofi expanded their portfolios through acquisitions, and several companies announced positive clinical trial results.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Truist Securiti | $100 | $80 | +25% |
| 2025-12-22 | HC Wainwright & | $60 | $55 | +9% |
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Truist Securiti | main | Buy |
| 2025-12-22 | HC Wainwright & | main | Neutral |
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.46 indicates undervaluation relative to growth. Forward P/E 11.3x attractive for 49% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.46 |
| Forward P/E | 11.3 |
| Current P/E | 16.8 |
| YoY Growth | 48.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 12.4% to 7.8% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 97th percentile. MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 8.7% shows strong absolute momentum above own 20MA. Outperforming sector by 7.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.84), confirming momentum. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.75% (CS: 97) | Strong |
| RSI_14 | 64.4 | Neutral |
| MACD Histogram | 0.84 | Bullish |
| vs SMA20 | 1.087x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.039x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $59.95
- **Stop Loss:** $55.91 (6.7% risk)
- **Target:** $66.01 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 326
- **Position Value:** $19,543.70
- **Portfolio %:** 19.54%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.34 | $0.12 | -64.3% |
| 2025Q2 | $1.03 | $1.44 | +39.4% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*